Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
CB1 cannabinoid receptor
OXIZID
bioassay
new psychoactive substances
synthetic cannabinoid receptor agonists
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
06
05
2022
received:
17
01
2022
accepted:
09
05
2022
pubmed:
14
5
2022
medline:
17
9
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
In recent years, several nations have implemented various measures to control the surge of new synthetic cannabinoid receptor agonists (SCRAs) entering the recreational drug market. In July 2021, China put into effect a new generic legislation, banning SCRAs containing one of seven general core scaffolds. However, this has driven manufacturers towards the synthesis of SCRAs with alternative core structures, exemplified by the recent emergence of "OXIZID SCRAs." Here, using in vitro β-arrestin2 recruitment assays, we report on the CB
Substances chimiques
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Illicit Drugs
0
Receptor, Cannabinoid, CB1
0
Receptor, Cannabinoid, CB2
0
Receptors, Cannabinoid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1565-1575Subventions
Organisme : Research Foundation-Flanders
ID : 1S54521N
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
United Nations Office on Drugs and Crime. World drug report 2021. 2021. Accessed November 24, 2021. https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html
European Monitoring Centre for Drugs and Drug Addiction, ed. European Drug Report: Trends and Developments 2020. Publications Office of the European Union; 2020. https://www.emcdda.europa.eu/system/files/publications/13236/TDAT20001ENN_web.pdf
Duke K. Producing the ‘problem’ of new psychoactive substances (NPS) in English prisons. Int J Drug Policy. 2020;80. doi:10.1016/j.drugpo.2019.05.022
Gray P, Ralphs R, Williams L. The use of synthetic cannabinoid receptor agonists (SCRAs) within the homeless population: motivations, harms and the implications for developing an appropriate response. Addict Res Theory. 2021;29(1):1-10. doi:10.1080/16066359.2020.1730820
Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234-243. doi:10.1016/j.pnpbp.2012.04.017
Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol Phila Pa. 2011;49(8):760-764. doi:10.3109/15563650.2011.609822
Kemp AM, Clark MS, Dobbs T, Galli R, Sherman J, Cox R. Top 10 facts you need to know about synthetic cannabinoids: not so nice spice. Am J Med. 2016;129(3):240, e1-244. doi:10.1016/j.amjmed.2015.10.008
European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: synthetic cannabinoids in Europe. 2017. Accessed March 21, 2022. https://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf
Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31-39. doi:10.1016/j.forsciint.2015.12.046
Manini AF, Krotulski AJ, Schimmel J, et al. Respiratory failure in confirmed synthetic cannabinoid overdose. Clin Toxicol. 2021;60(4):524-526. doi:10.1080/15563650.2021.1975734
Bukke VN, Archana M, Villani R, Serviddio G, Cassano T. Pharmacological and toxicological effects of phytocannabinoids and recreational synthetic cannabinoids: increasing risk of public health. Pharmaceuticals. 2021;14(10):965. doi:10.3390/ph14100965
Riederer AM, Campleman SL, Carlson RG, et al. Acute poisonings from synthetic cannabinoids-50 U.S. toxicology investigators consortium registry sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(27):692-695. doi:10.15585/mmwr.mm6527a2
Abouchedid R, Hudson S, Thurtle N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol. 2017;55(5):338-345. doi:10.1080/15563650.2017.1287373
Office of China National Narcotics Control Commission. Announcement on the inclusion of 18 substances including synthetic cannabinoids and fluamine in the Supplementary List of Controlled Narcotic Drugs and Psychotropic Substances with Non-medical Use. Published online May 12, 2021. https://app.mps.gov.cn/gdnps/pc/content.jsp?id=7881703
The Center for Forensic Science Research & Education, Cayman Chemical. New systematic naming for synthetic cannabinoid “MDA-19” and its related analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID. Published online August 31, 2021. Accessed November 25, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/08/New-Systematic-Naming-for-MDA-19-and-Related-Analogues_NPS-Discovery_083121.pdf
Cayman Chemical. BZO-4en-POXIZID product information. Published online November 11, 2021. Accessed December 1, 2021. https://cdn.caymanchem.com/cdn/insert/35503.pdf
van Amsterdam J, Nutt D, van den Brink W. Generic legislation of new psychoactive drugs. J Psychopharmacol (Oxf). 2013;27(3):317-324. doi:10.1177/0269881112474525
United Nations Office on Drugs and Crime. News: April 2019-China: announcement to place all fentanyl-related substances under national control. Published April 2019. Accessed November 25, 2021. https://www.unodc.org/LSS/Announcement/Details/f2adea68-fbed-4292-a4cc-63771c943318
United Nations Office on Drugs and Crime. News: May 2021-China: announcement to place synthetic cannabinoids under generic control. Published May 2021. Accessed November 24, 2021. https://www.unodc.org/LSS/Announcement/Details/ff032a29-2e14-4dab-b7d8-ab86d355c809
Liu CM, Hua ZD, Jia W, Li T. Identification of AD-18, 5F-MDA-19, and pentyl MDA-19 in seized materials after the class-wide ban of synthetic cannabinoids in China. Drug Test Anal. Published online October 25. 2021. doi:10.1002/dta.3185
Li X, Shen L, Hua T, Liu ZJ. Structural and functional insights into cannabinoid receptors. Trends Pharmacol Sci. 2020;41(9):665-677. doi:10.1016/j.tips.2020.06.010
Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470. doi:10.1007/s00018-016-2300-4
Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319-334. doi:10.1038/sj.bjp.0707531
Hashiesh HM, Sharma C, Goyal SN, Jha NK, Ojha S. Pharmacological properties, therapeutic potential and molecular mechanisms of JWH133, a CB2 receptor-selective agonist. Front Pharmacol. 2021;12:1818. doi:10.3389/fphar.2021.702675
Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 (CB2) receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018;31(4):407-414. doi:10.1097/ACO.0000000000000616
Malan TP, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol. 2003;3(1):62-67. doi:10.1016/S1471-4892(02)00004-8
Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem. 2008;51(16):4932-4947. doi:10.1021/jm8002203
Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010;111(1):99-109. doi:10.1213/ANE.0b013e3181e0cdaf
St. John Smith E. Advances in understanding nociception and neuropathic pain. J Neurol. 2018;265(2):231-238. doi:10.1007/s00415-017-8641-6
Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;429(1):1-11. doi:10.1016/S0014-2999(01)01302-4
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-819. doi:10.1016/S1474-4422(10)70143-5
Rao M, Chen D, Zhan P, Jiang J. MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct. 2019;14(1):9. doi:10.1186/s13062-019-0241-1
Liu B, Xu L, Dai EN, Tian JX, Li JM. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway. Biosci Rep. 2018;38(6):BSR20181501. doi:10.1042/BSR20181501
Dang N, Meng X, Ma S, et al. MDA-19 suppresses progression of melanoma via inhibiting the PI3K/Akt pathway. Open Med. 2018;13(1):416-424. doi:10.1515/med-2018-0061
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2016 Annual Report on the Implementation of Council Decision 2005/387/JHA. 2016. https://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf
The Center for Forensic Science Research & Education. BZO-HEXOXIZID chemistry report. 2021. Accessed November 25, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/10/BZO-HEXOXIZID_101921_CFSRE-Chemistry_Report.pdf?mc_cid=c736522745&mc_eid=da2366d692
The Center for Forensic Science Research & Education. 5F-BZO-POXIZID chemistry report. 2021. Accessed November 25, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/10/5F-BZO-POXIZID_101921_CFSRE-Chemistry_Report.pdf?mc_cid=c736522745&mc_eid=da2366d692
The Center for Forensic Science Research & Education. BZO-POXIZID chemistry report. 2021. Accessed November 25, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/10/BZO-POXIZID_101921_CFSRE-Chemistry_Report.pdf?mc_cid=c736522745&mc_eid=da2366d692
The Center for Forensic Science Research & Education. BZO-CHMOXIZID chemistry report. 2021. Accessed November 25, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/11/BZO-CHMOXIZID_111821_CFSRE-Chemistry_Report.pdf?mc_cid=0ee18051f6&mc_eid=da2366d692
The Center for Forensic Science Research & Education. 2021 Q1 Synthetic cannabinoids trend report. 2021. Accessed December 1, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/04/2021-Q1_Synthetic-Cannabinoids_Trend-Report.pdf
The Center for Forensic Science Research & Education. 2021 Q2 Synthetic cannabinoids trend report. 2021. Accessed December 1, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/07/2021-Q2_Synthetic-Cannabinoids_Trend-Report.pdf
The Center for Forensic Science Research & Education. 2021 Q3 Synthetic cannabinoids trend report. 2021. Accessed December 1, 2021. https://www.npsdiscovery.org/wp-content/uploads/2021/10/2021-Q3_Synthetic-Cannabinoids_Trend-Report.pdf
Ministry of Justice. Notification 2021/0903/HU: Amendment of Decree No 55/2014 of the Ministry of Human Capacities of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances. 2021. Accessed January 5, 2022. https://ec.europa.eu/growth/tools-databases/tris/en/search/?trisaction=search.detail&year=2021&num=903
Ministry of Justice. Notification 2021/0840/HU: Amendment of Decree No 55/2014 of the Ministry of Human Capacities of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances. 2021. Accessed January 10, 2022. https://ec.europa.eu/growth/tools-databases/tris/index.cfm/en/search/?trisaction=search.detail&year=2021&num=840&mLang=EN
Cannaert A, Storme J, Franz F, Auwärter V, Stove CP. Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem. 2016;88(23):11476-11485. doi:10.1021/acs.analchem.6b02600
Cannaert A, Franz F, Auwärter V, Stove CP. Activity-based detection of consumption of synthetic cannabinoids in authentic urine samples using a stable cannabinoid reporter system. Anal Chem. 2017;89(17):9527-9536. doi:10.1021/acs.analchem.7b02552
Cannaert A, Storme J, Hess C, Auwärter V, Wille SMR, Stove CP. Activity-based detection of cannabinoids in serum and plasma samples. Clin Chem. 2018;64(6):918-926. doi:10.1373/clinchem.2017.285361
Cannaert A, Sparkes E, Pike E, et al. Synthesis and in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chem Neurosci. 2020;11(24):4434-4446. doi:10.1021/acschemneuro.0c00644
Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP. In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: fluorination versus isomer exploration. Drug Test Anal. 2020;12(9):1336-1343. doi:10.1002/dta.2870
Wouters E, Mogler L, Cannaert A, Auwärter V, Stove C. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine. Drug Test Anal. 2019;11(8):1183-1191. doi:10.1002/dta.2607
Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol. 2011;80(3):367-377. doi:10.1124/mol.111.072801
Pottie E, Dedecker P, Stove CP. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays. Biochem Pharmacol. 2020;182:114251. doi:10.1016/j.bcp.2020.114251
Vandeputte MM, Van Uytfanghe K, Layle NK, St. Germaine DM, Iula DM, Stove CP. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of “nitazene” 2-benzylbenzimidazole synthetic opioids. ACS Chem Nerosci. 2021;12(7):1241-1251. doi:10.1021/acschemneuro.1c00064
Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48(3):443-450.
Blanckaert P, Cannaert A, Van Uytfanghe K, et al. Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical and in vitro functional characterization of isotonitazene. Drug Test Anal. 2020;12(4):422-430. doi:10.1002/dta.2738
Thoren KL, Colby JM, Shugarts SB, Wu AHB, Lynch KL. Comparison of information-dependent acquisition on a tandem quadrupole TOF vs a triple quadrupole linear ion trap mass spectrometer for broad-spectrum drug screening. Clin Chem. 2016;62(1):170-178. doi:10.1373/clinchem.2015.241315
Lobo Vicente J, Chassaigne H, Holland MV, et al. Systematic analytical characterization of new psychoactive substances: a case study. Forensic Sci Int. 2016;265:107-115. doi:10.1016/j.forsciint.2016.01.024
Wouters E, Walraed J, Banister SD, Stove CP. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochem Pharmacol. 2019;169:113623. doi:10.1016/j.bcp.2019.08.025
Wiley JL, Compton DR, Dai D, et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther. 1998;285(3):995-1004.
Antonides LH, Cannaert A, Norman C, et al. Shape matters: the application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. Drug Test Anal. 2021;13(3):628-643. doi:10.1002/dta.2965
Ametovski A, Cairns EA, Grafinger KE, et al. NNL-3: a synthetic intermediate or a new class of hydroxybenzotriazole esters with cannabinoid receptor activity? ACS Chem Nerosci. 2021;12(21):4020-4036. doi:10.1021/acschemneuro.1c00348
Banister SD, Moir M, Stuart J, et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Nerosci. 2015;6(9):1546-1559. doi:10.1021/acschemneuro.5b00112